AZN
Astrazeneca·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AZN
Astrazeneca Plc
A global, innovation-driven biopharmaceutical leader developing and commercializing medicines for various diseases
Pharmaceutical
06/17/1992
09/28/2020
NASDAQ Stock Exchange
94,300
12-31
Depository Receipts (Ordinary Shares)
1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge, CB2 0AA England
Development and sales of prescription drugs such as cardiovascular and digestive system infections, neuro-oncology, respiratory inflammation, etc
AstraZeneca AG was incorporated in England and Wales on 17 June 1992 under the Companies Act 1985. The company was formed in 1993 when Imperial Chemical Industries spun off its pharmaceutical, agrochemical and specialty chemicals businesses. In 1999, the company sold its specialty chemicals business. Also in 1999, the company merged with the Swedish company Astra. In 2000, the company spun off its agrochemical business and merged it with a similar business of Novartis to form a new company, Syngenta AG. In 2007, the Group acquired MedImmune, a biologics and vaccine company based in the United States. In 2021, the Group acquired Alexion, a rare disease company based in the United States.
Earnings Call
Q1/2025
Estimate EPS1.11
Actual EPS2.49
Estimate Revenue13.72B
Actual Revenue13.59B
SOPHiA Genetics Q1 2025: Unraveling Contradictions in Biopharma Revenue and Strategic Growth
May 10,2025 03:06
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.1
Actual EPS2.17
Estimate Revenue14.10B
Actual Revenue14.46B
Compugen's Q2 2025: Contradictions Uncovered in COM701 Trial Progress and Market Potential
Aug 06,2025 05:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AZN has released its 2025 Q3 earnings. EPS was reported at 2.38, versus the expected 1.13, beating expectations. The chart below visualizes how AZN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AZN has released its 2025 Q3 earnings report, with revenue of 15.19B, reflecting a YoY change of 11.99%, and net profit of 2.54B, showing a YoY change of 76.90%. The Sankey diagram below clearly presents AZN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
